Schonfeld Reduces Vaxcyte Holdings

Summary

Schonfeld Strategic Advisors LLC reduced its holdings in Vaxcyte, Inc. by 74.8% during the fourth quarter. The current holding is 20,400 shares after selling 60,610 shares. Other institutional investors also adjusted their holdings. Vaxcyte’s stock opened at $29.24, with a 12-month price range of $27.66 to $121.06. Analysts’ ratings are mixed, with an average target price of $136.50. Vaxcyte focuses on developing novel protein vaccines against bacterial diseases.Market Beat

Impact Analysis

The event is classified at the company level as it specifically involves Vaxcyte, Inc. The reduction in holdings by Schonfeld and other investors indicates potential concerns about the company’s near-term prospects or a reassessment of its valuation. The mixed analyst ratings and recent price range suggest market uncertainty. Despite some analysts maintaining a ‘buy’ rating, the absence of Vaxcyte from top recommended stocks points to lukewarm sentiment.Market Beat+ 2 The company’s ongoing Vax-31 study and significant capital expenditures for facility development could influence future stock performance if milestones are met.Reuters+ 2 Investors should consider these factors and monitor upcoming clinical results and completion of facility investments as potential catalysts for stock movement.